BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Vitamin E
,
rs4950928
,
CYP51
,
T cell differentiation
,
Influenza
,
Hippocampus
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
agents, i
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Drug target sets for approved compounds
Broad Connectivity Map (CMAP 2.0) compound database
Explore Curated Studies Results
Literature
Most Relevant Literature
Eventual success rate and predictors of success for oncology drugs tested in phase I trials.
Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development.
Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Ph…
Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological…
Novel diindoloazepinone derivatives as DNA minor groove binding agents with selective topoisomerase …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal …
Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanc…
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ